COL-3-Induced Molecular and Ultrastructural Alterations in K562 Cells.
COL-3
K562 cells
m-calpain
paraptosis
programmed necrosis
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
04 Jan 2022
04 Jan 2022
Historique:
received:
03
12
2021
revised:
28
12
2021
accepted:
30
12
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Tetracycline-3 (4-dedimethylamino sancycline, COL-3) is a non-antibiotic tetracycline derivative. COL-3 exerts potent anti-metalloproteinase activity and its antitumor effects have been reported both in vitro and in vivo. In this study, we investigated the mechanisms of COL-3-induced cytotoxicity in a chronic myeloid leukemia cell line, K562, characterized by the BCR-ABL fusion protein. COL-3 induced K562 cell death in a concentration-dependent manner with an IC50 of 10.8 µg/mL and exhibited features of both apoptosis and necrosis. However, flow cytometry analysis revealed that necrotic cells dominated over the early and late apoptotic cells upon treatment with COL-3. Transmission electron microscopy analysis in combination with Western blotting (WB) analysis revealed early mitochondrial swelling accompanied by the early release of cytochrome c and truncated apoptosis inducing factor (tAIF). In addition, ultrastructural changes were detected in the endoplasmic reticulum (ER). COL-3 affected the levels of glucose-regulated protein-94 (GRP94) and resulted in m-calpain activation. DNA double strand breaks as a signature for DNA damage was also confirmed using an antibody against γH2AX. WB analyses did not demonstrate caspase activation, while Bcl-xL protein remained unaffected. In conclusion, COL-3-induced cell death involves DNA damage as well as mitochondrial and ER perturbation with features of paraptosis and programmed necrosis.
Identifiants
pubmed: 35055357
pii: jpm12010042
doi: 10.3390/jpm12010042
pmc: PMC8778770
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Karolinska Institute
ID : 20200788 (CiMED)
Organisme : Barncancerfonden
ID : PR2020-0151
Organisme : Swedish Cancer Society
ID : CAN2011/595
Organisme : Karolinska Institute
ID : 2018-02377
Organisme : Radium Hemmets Research Funds
ID : 161082
Références
J Cell Mol Med. 2010 Apr;14(4):970-81
pubmed: 20569277
Trends Mol Med. 2006 Sep;12(9):440-50
pubmed: 16899408
Cell Death Differ. 2012 Jan;19(1):107-20
pubmed: 21760595
Blood. 2014 Jun 19;123(25):3932-42
pubmed: 24825862
J Clin Oncol. 2006 Mar 20;24(9):1389-94
pubmed: 16549833
Nat Rev Cancer. 2020 Mar;20(3):158-173
pubmed: 31907378
Cell Death Differ. 2009 Jan;16(1):3-11
pubmed: 18846107
Int J Biol Macromol. 2003 Nov;33(1-3):49-56
pubmed: 14599584
Int J Cancer. 2002 Mar 10;98(2):297-309
pubmed: 11857423
FEBS J. 2019 Jan;286(2):241-278
pubmed: 30027602
Apoptosis. 2006 Sep;11(9):1463-71
pubmed: 16820960
Cell. 2011 Nov 11;147(4):742-58
pubmed: 22078876
Cancer Res. 1981 Jan;41(1):237-43
pubmed: 6934848
Science. 2002 Jul 12;297(5579):259-63
pubmed: 12114629
Nature. 1999 Jun 3;399(6735):483-7
pubmed: 10365962
Leukemia. 2002 Oct;16(10):2165-7
pubmed: 12357376
Biochimie. 2002 Feb-Mar;84(2-3):153-66
pubmed: 12022946
Cell Death Differ. 2005 Nov;12 Suppl 2:1478-80
pubmed: 16247494
J Pharm Sci. 1999 May;88(5):535-7
pubmed: 10229645
J Cell Biol. 2000 Sep 18;150(6):1489-98
pubmed: 10995452
Annu Rev Genet. 2009;43:95-118
pubmed: 19659442
Int J Cancer. 2006 Mar 1;118(5):1309-15
pubmed: 16152604
J Clin Oncol. 2002 Jan 1;20(1):153-9
pubmed: 11773164
PLoS One. 2014 Dec 15;9(12):e114457
pubmed: 25502932
Mol Cancer Ther. 2013 Oct;12(10):2078-87
pubmed: 23939379
Biochim Biophys Acta. 2009 Dec;1793(12):1848-59
pubmed: 19833151
Ann Clin Biochem. 2005 Nov;42(Pt 6):415-31
pubmed: 16259792
Leukemia. 2011 May;25(5):761-9
pubmed: 21350558
Adv Dent Res. 1998 Nov;12(2):5-11
pubmed: 9972116
FEBS Lett. 2000 Jul 7;476(3):118-23
pubmed: 10913597
Cell Chem Biol. 2018 Dec 20;25(12):1506-1518.e13
pubmed: 30318461
Science. 1975 Sep 12;189(4206):867
pubmed: 17812524
Cell Cycle. 2007 Nov 1;6(21):2612-9
pubmed: 17912035
Crit Rev Oncol Hematol. 2019 May;137:57-83
pubmed: 31014516
Leuk Res Treatment. 2012;2012:671702
pubmed: 23259070
FEBS J. 2015 Jan;282(1):19-31
pubmed: 25327580
Surg Neurol. 1985 Jul;24(1):67-72
pubmed: 4012564